Suppr超能文献

用于心脏应用的可规模化和稳定的人多能干细胞衍生的类微血管内皮细胞的生成和特性分析。

Generation and characterisation of scalable and stable human pluripotent stem cell-derived microvascular-like endothelial cells for cardiac applications.

机构信息

National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, W12 0NN, UK.

Drug Research Programme, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

出版信息

Angiogenesis. 2024 Aug;27(3):561-582. doi: 10.1007/s10456-024-09929-5. Epub 2024 May 22.

Abstract

Coronary microvascular disease (CMD) and its progression towards major adverse coronary events pose a significant health challenge. Accurate in vitro investigation of CMD requires a robust cell model that faithfully represents the cells within the cardiac microvasculature. Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) offer great potential; however, they are traditionally derived via differentiation protocols that are not readily scalable and are not specified towards the microvasculature. Here, we report the development and comprehensive characterisation of a scalable 3D protocol enabling the generation of phenotypically stable cardiac hPSC-microvascular-like ECs (hPSC-CMVECs) and cardiac pericyte-like cells. These were derived by growing vascular organoids within 3D stirred tank bioreactors and subjecting the emerging 3D hPSC-ECs to high-concentration VEGF-A treatment (3DV). Not only did this promote phenotypic stability of the 3DV hPSC-ECs; single cell-RNA sequencing (scRNA-seq) revealed the pronounced expression of cardiac endothelial- and microvascular-associated genes. Further, the generated mural cells attained from the vascular organoid exhibited markers characteristic of cardiac pericytes. Thus, we present a suitable cell model for investigating the cardiac microvasculature as well as the endothelial-dependent and -independent mechanisms of CMD. Moreover, owing to their phenotypic stability, cardiac specificity, and high angiogenic potential, the cells described within would also be well suited for cardiac tissue engineering applications.

摘要

冠状动脉微血管疾病(CMD)及其向主要不良冠状动脉事件的进展构成了重大的健康挑战。准确的 CMD 体外研究需要一个稳健的细胞模型,该模型能真实地代表心脏微血管中的细胞。人多能干细胞衍生的内皮细胞(hPSC-ECs)具有巨大的潜力;然而,它们传统上是通过分化方案衍生的,这些方案不易扩展,并且不能针对微血管进行特异性分化。在这里,我们报告了一种可扩展的 3D 方案的开发和全面表征,该方案能够生成表型稳定的心脏 hPSC-微血管样内皮细胞(hPSC-CMVECs)和心脏周细胞样细胞。这些细胞是通过在 3D 搅拌罐生物反应器中生长血管类器官,并对新出现的 3D hPSC-ECs 进行高浓度 VEGF-A 处理(3DV)来获得的。这不仅促进了 3DV hPSC-ECs 的表型稳定性;单细胞 RNA 测序(scRNA-seq)揭示了心脏内皮细胞和微血管相关基因的显著表达。此外,从血管类器官中获得的生成的壁细胞表现出心脏周细胞的特征性标志物。因此,我们提出了一种适合研究心脏微血管以及 CMD 的内皮依赖性和非依赖性机制的细胞模型。此外,由于其表型稳定性、心脏特异性和高血管生成潜力,所描述的细胞也非常适合心脏组织工程应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97cd/11303486/40f96d23d6fa/10456_2024_9929_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验